Enzo Biochem Inc. (NYSE:ENZ) released its quarterly earnings results on Thursday. The company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.83. The company earned $26.60 million during the quarter, compared to the consensus estimate of $26 million. Enzo Biochem had a negative return on equity of 20.77% and a net margin of 17.27%. During the same quarter in the prior year, the company posted ($0.06) EPS.
Enzo Biochem (NYSE:ENZ) traded down 0.39% during mid-day trading on Thursday, hitting $5.07. The stock had a trading volume of 112,426 shares. Enzo Biochem has a 52 week low of $3.48 and a 52 week high of $7.00. The stock’s 50-day moving average is $5.36 and its 200 day moving average is $5.69. The company has a market capitalization of $234.56 million, a P/E ratio of 13.27 and a beta of 1.50.
Separately, Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 9th.
Hedge funds have recently modified their holdings of the company. BlackRock Fund Advisors increased its stake in shares of Enzo Biochem by 1,067.3% in the second quarter. BlackRock Fund Advisors now owns 1,030,773 shares of the company’s stock valued at $6,154,000 after buying an additional 942,472 shares during the last quarter. State Street Corp increased its stake in shares of Enzo Biochem by 2,158.8% in the second quarter. State Street Corp now owns 494,216 shares of the company’s stock valued at $2,949,000 after buying an additional 472,336 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Enzo Biochem by 24.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,628,583 shares of the company’s stock valued at $9,723,000 after buying an additional 315,111 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Enzo Biochem by 11.9% in the second quarter. Vanguard Group Inc. now owns 1,494,933 shares of the company’s stock valued at $8,925,000 after buying an additional 159,423 shares during the last quarter. Finally, BlackRock Investment Management LLC increased its stake in shares of Enzo Biochem by 2,287.4% in the second quarter. BlackRock Investment Management LLC now owns 151,049 shares of the company’s stock valued at $902,000 after buying an additional 144,722 shares during the last quarter. 53.29% of the stock is currently owned by institutional investors and hedge funds.
About Enzo Biochem
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.